M. Cecilia Bahit

Adiponectin and its mimetics reduce infarct size and improve function in ischemia-reperfusion models.

Adiponectin modulation may merit further study in MIRI; leaves open translation to clinical STEMI reperfusion.

Sacubitril/valsartan lowers NT-proBNP by ~32% vs. enalapril in Chagas HFrEF.

Sacubitril/valsartan lowers NT-proBNP more than enalapril in Chagas HFrEF; extends ARNI benefits to this etiology.

AUG 2025UdellThe Lancet

Elevated estimated plasma volume status (adjusted HR 1.294) and neutrophil-to-lymphocyte ratio (adjusted HR 1.029) were independently associated with increased long-term cardiovascular mortality in patients with acute myocardial infarction complicated by heart failure.

The combined assessment of volume overload (via ePVS) and systemic inflammation (via NLR) significantly enhances the prognostic accuracy for long-term cardiovascular mortality in patients with heart failure complicating acute myocardial infarction.

SEP 2015VinereanuEuropean Heart Journal

Women with AF on apixaban or warfarin have similar stroke risk to men.

Apixaban provides consistent efficacy and safety benefits over warfarin in both men and women with atrial fibrillation, despite women having lower baseline risks of mortality and bleeding.

SEP 2024GibsonJournal of the American College of Cardiology

CSL112 reduces 1-year total ischemic events and CV death ~11% vs. placebo.

In a prespecified exploratory analysis of the AEGIS-II trial, 4 weekly infusions of CSL112 significantly reduced the total burden of nonfatal ischemic events and CV death at 180 and 365 days compared with placebo in high-risk patients after AMI.

Neurocardiogenic syndromes drive post-stroke CV complications via brain-heart interactions, causing over 1.5 million deaths worldwide.

Hypothesis-generating for post-stroke cardiac protection; leaves open randomized trials before clinical adoption.

Cardiovascular disease accounts for ~35% of all female deaths globally.

Heightened awareness of CVD symptoms and care barriers in women is warranted; leaves open effective interventions for socioeconomic disparities.

Sacubitril/Valsartan vs Enalapril in Heart Failure Due to Chagas Disease

Randomized trial showed similar mortality in heart failure from Chagas disease, but treatment with sacubitril/valsartan improved NT-proBNP levels significantly.

NOV 2025GibsonCirculation

Proactive trial strategies minimize missing data to preserve clinical trial integrity.

This article provides a roadmap and strategies to proactively minimize missing data in clinical trials to preserve the integrity of trial results.

Patients with CCC-related HFrEF exhibit a unique clinical profile characterized by a higher proportion of women, lower rates of hypertension and diabetes, and higher prevalence of stroke and pacemaker implantation compared to non-CCC HFrEF.

Baseline data from the PARACHUTE-HF trial demonstrates that patients with Chagas cardiomyopathy-related HFrEF have a distinct clinical profile, emphasizing the need for dedicated treatments in this population.

Vision impairment following glucagon-like peptide-1 receptor agonist use: is it harmful?

CSL112 reduced MACE in post-AMI patients with elevated baseline neutrophil-lymphocyte ratio and LDL-C ≥100 mg/dL (P=0.029).

In an exploratory post hoc analysis, CSL112 was associated with a reduction in MACE among post-AMI patients who had both elevated systemic inflammation (NLR) and LDL-C ≥100 mg/dL.

DEC 2024PetrieENLIGHTEN (Jurnal Bimbingan dan Konseling Islam)

Empagliflozin reduces HF hospitalizations after acute MI regardless of diabetes status.

Empagliflozin reduces heart failure hospitalizations in patients with acute myocardial infarction complicated by reduced LVEF or congestion, irrespective of their baseline type 2 diabetes status.

Ischemic stroke prevention in patients with atrial fibrillation and a recent ischemic stroke, TIA, or intracranial hemorrhage: A World Stroke Organization (WSO) scientific statement

Guides early anticoagulation use in AF-related stroke; leaves open optimal AF screening, LAA closure, and breakthrough stroke strategies.

Barriers and facilitators to implementation of intravenous cardiovascular treatments in ambulatory settings

Aims Intravenous (IV) therapies have transformed the management of various cardiovascular conditions in ambulatory patients. However, uptake of these therapies in ambulatory care settings has several barriers. In this systematic scoping review, we aimed to identify the barriers and facilitators that influence the implementation of current IV therapies in ambulatory settings. Methods We searched MEDLINE, Embase and CINAHL databases from inception to September 2023 for studies on barriers and facilitators of IV therapy uptake in ambulatory patients. We classified the identified factors and performed a thematic analysis. Results Fifteen studies, primarily conducted in North America and Europe, were included. Methodologies varied, precluding quantitative synthesis. Key barriers were identified across several levels. At the medication level, barriers included the need for multiple vials and lengthy preparation. Patient‐level barriers included adverse effects, infections, painful venous access and non‐adherence. Clinician‐level barriers included understaffing, time constraints and safety concerns. Institutional barriers ranged from staff or equipment shortages to liability concerns and complex logistics. Healthcare system barriers included financial constraints and limited care delivery services. Facilitators included evidence‐based indications, patient education and comfort, staff experience, guidance documents, safe settings, favourable insurance policies and supportive guidelines. Conclusions As novel IV treatments emerge, addressing barriers and leveraging facilitators preemptively can enhance the successful implementation of IV therapies and improve clinical outcomes in ambulatory settings.

AUG 2024GibsonEuropean Heart Journal

Apolipoprotein A-I Infusions and Cardiovascular Outcomes in Acute Myocardial Infarction According to Baseline LDL-Cholesterol Levels: The AEGIS-II Trial

Randomized trial post-hoc analysis shows CSL112 reduces cardiovascular events after acute myocardial infarction with elevated LDL cholesterol, indicating baseline-dependent benefit.